NCT05318963View on ClinicalTrials.gov

Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

January 17, 2025

Study Completion Date

March 31, 2025

Conditions
B-cell Lymphoma RecurrentB-cell Lymphoma Refractory
Interventions
BIOLOGICAL

LCAR-AIO cells product

before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days.

Trial Locations (2)

300020

Institute of Hematology & Blood Diseases Hospital, Tianjin

Unknown

Beijing Gobroad Boren Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

Nanjing Legend Biotech Co.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER